[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"locally-advanced-pancreatic-adenocarcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:locally-advanced-pancreatic-adenocarcinoma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,22,0,[8,42,72,93,118,142,164,195,221,243,275,297,329,356,377,403,432,455,482,504,527,551],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100375748","phase-1-testing-the-addition-of-a-new-anti-cancer-drug-m3814-peposertib-to-the-usual-radiotherapy-in-patients-with-locally-advanced-pancreatic-cancer-100375748",false,"NCT04172532","Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer","A Phase 1\u002F2 Study of M3814 (Peposertib) in Combination With Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma","Inclusion Criteria:\n\n* Patients must have pathologically confirmed pancreatic adenocarcinoma. Patients with alternative or mixed histologies (i.e., squamous, neuroendocrine, acinar, colloid) are not eligible\n* Received 4-6 months of induction chemotherapy with fluorouracil, irinotecan, leucovorin and oxaliplatin (FOLFIRINOX), fluorouracil, liposomal irinotecan, leucovorin, oxaliplatin (NALIRIFOX), or gemcitabine\u002FAbraxane, as per standard of care\n* Patients must have locally advanced pancreatic cancer according to National Comprehensive Cancer Network (NCCN) Guidelines (version 1.2020) on pancreas protocol CT scan performed within 21 days of registration. Locally advanced disease is defined as any of the following:\n\n  * For head or uncinate process tumors:\n\n    * Solid tumor contact with superior mesenteric artery \\> 180 degrees\n    * Solid tumor contact with the celiac axis \\> 180 degrees\n    * Solid tumor contact with the common or proper hepatic arteries \\> 180 degrees or\n  * For pancreatic body or tail tumors:\n\n    * Solid tumor contact of \\> 180 degrees with the superior mesenteric artery or celiac axis\n    * Solid tumor contact with the celiac axis and aortic involvement or\n  * Unreconstructible superior mesenteric vein or portal vein due to tumor involvement or occlusion (can be due to tumor or bland thrombus)\n* The determination of locally advanced pancreatic cancer and plan for non-operative treatment on this clinical trial must be confirmed through local multi-disciplinary review\n* Measurable disease per response evaluation criteria in solid tumors (RECIST) version (v)1.1\n* Age \\>= 18 years. Because no dosing or adverse event data are currently available on the use of M3814 (peposertib) in combination with hypofractionated radiation in patients \\\u003C 18 years of age, children are excluded from this study, but will be eligible for future pediatric trials\n* Eastern Cooperative Oncology Group (ECOG) performance status =\\\u003C 2 (Karnofsky \\>= 60%)\n* Leukocytes \\>= 4,000\u002FmcL\n* Absolute neutrophil count \\>= 1.5 x 10\\^9\u002FL.\n* Hemoglobin \\>= 9 g\u002FdL\n* Platelets \\>= 100 x 10\\^9\u002FL\n* Total bilirubin =\\\u003C 2.0 x institutional upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \\[SGOT\\])\u002Falanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \\[SGPT\\]) =\\\u003C 3 x institutional ULN\n* Creatinine =\\\u003C 1.5 x institutional ULN\n* Glomerular filtration rate (GFR) \\>= 51 mL\u002Fmin\u002F1.73 m\\^2\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial\n* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated\n* Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load\n* Female patients of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. Female patients of childbearing potential and male patients must be willing to use an adequate method of contraception for the course of the study through 12 weeks after the last dose of study medication.\n\n  * Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient.\n* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function. To be eligible for this trial, patients should be American Heart Association Stage B (people without current or previous symptoms of heart failure but with either structural heart disease, increased filling pressures in the heart or other risk factors) or better and New York Heart Association Functional Classification II (slight limitation of physical activity, comfortable at rest, ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain), or better\n* Ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) and\u002For family member available will also be eligible\n\nExclusion Criteria:\n\n* Patients who have completed induction chemotherapy less than 2 weeks or more than 8 weeks prior to study enrollment\n* Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \\> grade 1) with the exception of alopecia and neuropathy grade =\\\u003C 2\n* Patients who are receiving any other investigational agents\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to M3814 (peposertib)\n* Evidence of distant metastatic disease\n* More than 1 line of chemotherapy for the treatment of localized pancreatic cancer, unless the change in treatment was made only for toxicity\n* Prior abdominal radiation\n* Active inflammatory bowel disease or connective tissue disease\n* Inability to swallow oral medications or gastrointestinal disease limiting absorption of oral agents\n* History of anaphylactic reaction to iodinated intravenous (IV) contrast required for radiation simulation. Patients with mild reactions may be enrolled, but must receive premedications for contrast allergy prior to imaging\n* Patients who cannot discontinue concomitant medications or herbal supplements that are strong inhibitors or strong inducers of cytochrome P450 (CYP) isoenzymes CYP3A4\u002F5, CYP2C9, and CYP2C19. Concomitant use of substrates with a narrow therapeutic index that are metabolized by CYP1A2, CYP2B6, CYP2C8, and CYP3A4\u002F5 are also excluded.\n\n  * Use caution with other substrates of CYP3A4\u002F5, CYP1A2, CYP2B6, CYP2C8 and substrates of P-gp, BCRP, OCT1, OAT3, OATP1B1, OATP1B3, MATE1, and MATE-2K with a narrow therapeutic index. Close monitoring is advised.\n\nBecause the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment\u002Finformed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product. (Patient Drug Interactions Handout and Wallet Card) should be provided to patients\n\n* Patients who cannot discontinue concomitant proton-pump inhibitors (PPIs). Patients may confer with the study doctor to determine if such medications can be discontinued. These must be discontinued \\>= 5 days prior to study treatment. Patients do not need to discontinue calcium carbonate. H2 blockers and antacids are allowed.\n* Patients who have received a live attenuated vaccine within 30 days of dosing with M3814 (peposertib)\n* Patients with uncontrolled intercurrent illness\n* Patients with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Pregnant women are excluded from this study because M3814 (peposertib) is a DNA-protein kinase (PK) inhibitor with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with M3814 (peposertib), breastfeeding should be discontinued if the mother is treated with M3814 (peposertib)\n* Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of this investigational regimen","ALL","18 Years",{"count":19,"type":20},92,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This phase I\u002FII trial studies the safety, side effects and best dose of M3814 and to see how well it works when given together with radiation therapy in treating patients with pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced). M3814 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Giving M3814 and hypofractionated radiation therapy together may be safe, tolerable and\u002For more effective than radiation therapy alone in treating patients with locally advanced pancreatic cancer.",[27,28],"Locally Advanced Pancreatic Adenocarcinoma","Stage III Pancreatic Cancer AJCC v8","RECRUITING","2026-06-10",{"date":32,"type":33},"2026-06-11","ACTUAL",{"date":35,"type":33},"2021-01-11",{"date":37,"type":20},"2026-08-01",{"name":39,"class":40},"National Cancer Institute (NCI)","NIH",44,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":71},"100637571","phase-1-ab801-in-combination-with-chemotherapy-and-immunotherapy-for-the-treatment-of-patients-with-borderline-resectable-locally-advanced-or-metastatic-cholangiocarcinoma-or-pancreatic-cancer-100637571","NCT07619313","AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer","A Phase 1\u002F1b Trial of AB801 in Combination With Chemotherapy and PD-1\u002FPD-L1 Blockade in Patients With Cholangiocarcinoma or Pancreatic Adenocarcinoma","Inclusion Criteria:\n\n* Male or female ≥ 18 years of age and willing and able to provide informed consent\n* Previously untreated cytologically or histologically confirmed, at least one measurable lesion via Response Evaluation Criteria in Solid Tumors (RECIST 1.1) of cholangiocarcinoma or pancreatic adenocarcinoma meeting following criteria:\n\n  * Cholangiocarcinoma\n\n    * Borderline resectable\u002Flocally advanced cholangiocarcinoma: to be defined as unresectable disease on evaluation by a hepatobiliary multi-disciplinary tumor board\u002Fsurgeon based on tumor size\u002Flocation, vascular involvement, and absence of extrahepatic metastasis.\n    * Metastatic cholangiocarcinoma: Patients with metastatic cholangiocarcinoma patient who have not received prior systemic therapy\n  * Pancreatic adenocarcinoma\n\n    * Borderline resectable pancreatic adenocarcinoma: There are multiple definitions of borderline resectable pancreatic ductal adenocarcinoma (PDAC). For the purposes of this study, borderline resectable disease will be identified per the National Comprehensive Cancer Network (NCCN) criteria. Per this definition, borderline resectable PDAC is defined as the presence of any one or more of the following on CT:\n\n      * An interface between the tumor and superior mesenteric artery (SMA) or celiac axis (CA) measuring \\\u003C 180º of the circumference of the vessel wall.\n      * An interface between the tumor with the common hepatic artery without extension into the celiac axis or hepatic artery bifurcation allowing for safe and complete resection and reconstruction.\n      * An interface between the primary tumor and the superior mesenteric vein or portal vein (SMV-PV) measuring ≥ 180° of the circumference of the vessel wall\n      * Short-segment occlusion of the SMV-PV with normal vein above and below the level of obstruction that is amenable to resection and venous reconstruction\n      * An interface between the primary tumor and the inferior vena cava (IVC)\n    * Locally advanced pancreatic adenocarcinoma: Multiple guidelines defining locally advanced PDAC have been developed. For the purposes of this study, locally advanced PDAC cases will be identified per the definition developed by the NCCN. Per this definition, locally advanced PDAC is defined as presence of any one or more of the following on CT:\n\n      * Interface between the tumor and SMA or CV measuring \\> 180º of the circumference of the vessel wall or solid tumor contact with the CA and aortic involvement.\n      * Occlusion of the SMV-PV that is not amenable to resection and venous reconstruction\n  * Metastatic pancreatic adenocarcinoma: Patients with metastatic pancreatic adenocarcinoma who have not received prior systemic therapy\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Absolute neutrophil count (ANC) ≥ 1.5x10\\^9\u002FL\n* Platelets ≥ 100x10\\^9\u002FL\n* Hemoglobin ≥ 9 g\u002FdL\n* Creatinine clearance (Ccr) ≥ 50 mL\u002Fmin (as calculated by Modified Cockcroft-Gault formula)\n* Serum total bilirubin ≤ 2x upper limit of normal (ULN) or \\\u003C 3x ULN if Gilbert's syndrome\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \\[SGOT\\]) and alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase \\[SGPT\\]) ≤ 2.5 X ULN; \\\u003C 5x ULN in patients with liver metastases\n* Women with no childbearing potential because of surgery or who are at least 1 year postmenopausal (ie, 12 months post last menstrual period) or with menopause confirmed by follicle-stimulating hormone testing, OR\n* Women of childbearing potential (defined as any female who has experienced menarche and is not permanently sterile or post-menopausal) must use an effective nonhormonal method of contraception (intrauterine device or intrauterine system; condom or occlusive cap \\[diaphragm or cervical or vault caps\\] with spermicidal foam or gel or film or cream or suppository; or vasectomized male partner if he is the sole partner of that participant) or practice true abstinence for the duration of the study and for up to 14 months after the last systemic treatment\n* Male participants must use an effective method of contraception (condom or occlusive cap \\[diaphragm or cervical or vault caps\\] with spermicidal foam or gel or film or cream or suppository; or vasectomy) or practice true abstinence as defined throughout the study and for up to 11 months after the systemic treatment\n* Immunosuppressive doses of systemic medications, such as corticosteroids or absorbed topical corticosteroids (doses \\> 10 mg\u002Fday prednisone or equivalent) must be discontinued at least 2 weeks (14 days) before study treatment administration. Physiologic doses of corticosteroids (≤ 10 mg\u002Fday of prednisone or its equivalent) or short pulses of corticosteroids (≤ 3 days) may be permitted\n* Products with known potential to prolong the corrected QT (QTc) interval should be avoided when possible. When able will replace non-prolonging QTc acting drug when available and if medically necessary\n* Major surgery as defined by the Investigator must be completed at least 4 weeks before study treatment administration. Participants should have recovered from the surgical procedure prior to the first dose being administered\n* Adequate baseline tumor tissue sample for correlative studies\n\nExclusion Criteria:\n\n* Previous treatment with any of planned study drugs in cholangiocarcinoma, though patients with one cycle of gemcitabine\u002Fcisplatin\u002Fdurvalumab will be considered eligible\n* Previous treatment with any of planned study drugs in pancreatic adenocarcinoma, though patients with one cycle of FOLFIRINOX will be considered eligible\n* Peripheral neuropathy \\> grade 2\n* Known status of HIV which is not well-controlled (CD4 \\\u003C 300) at the time of study eligibility. Patients with controlled and treated HIV\u002Fhepatitis C virus (HCV) and an undetectable viral load are allowed\n* Untreated hepatitis B infection; Patient has known active hepatitis B virus (HBV) or hepatitis C virus (HCV), or human immunodeficiency virus (HIV) infection (testing is not mandatory, unless known active or known history of infection or required by local regulation):\n\n  * Participants with resolved or treated HCV (ie, HCV antibody positive but undetectable HCV ribonucleic acid \\[RNA\\]) will not be excluded from this study\n* Underlying medical conditions that, in the Investigator's opinion, will make the administration of investigational product (IP)(s) hazardous, including but not limited to:\n\n  * Interstitial lung disease, including history of interstitial lung disease or non-infectious pneumonitis\n  * Active viral, bacterial, or fungal infections requiring parenteral treatment within 14 days of the initiation of the IP,\n  * Active infection or antibiotics within 48 hours prior to study screening;\n  * A condition or unresolved adverse event (AE) from a prior investigational drug that may obscure the interpretation of toxicity determination or AEs,\n  * History of prior solid-organ transplantation\n* Any history of malignancy less than 5 years prior to the time of study eligibility (Patients with history of skin cancers excluding melanoma and cancers with a very low risk of recurrence i.e., low grade prostate cancer, thyroid cancer and low risk cervical cancer will be eligible for participation)\n* Serious medical comorbidities such as New York Heart Association Class III\u002FIV cardiac disease, uncontrolled cardiac arrhythmias, myocardial infarction over the past 12 months\n* Known family history or personal history of long QTc syndrome or previous drug-induced QTc prolongation of at least grade 3 (QTc \\> 500 ms)\n* Screening 12-lead electrocardiogram (ECG), in triplicate, with a measurable QTc interval of \\> 450ms\n* Known, existing uncontrolled coagulopathy. Patients who have had a venous thromboembolic event (e.g., pulmonary embolism or deep vein thrombosis) requiring anticoagulation are eligible IF: they are appropriately anticoagulated and have not had a grade 2 or greater bleeding episode in the 3 weeks before day 1\n* Known pregnancy, nursing women or positive pregnancy test. Requirement for women of childbearing potential (WOCBP): Negative serum pregnancy test at screening and serum or urine prior to dosing on cycle 1 day 1, within 24 hours prior to the start of treatment (minimum sensitivity 25 IU\u002FL or equivalent units of human chorionic gonadotropin \\[HCG\\]). WOCBP must also have a negative serum or urine pregnancy test every 3 weeks, within 24 hours prior to the start of treatment\n* Any condition (concurrent disease, infection, or comorbidity) that interferes with ability to participate in the study, causes undue risk, or complicates the interpretation of safety data, in the opinion of the investigator\n* History of trauma or major surgery within 28 days prior to the first dose of IP\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial\n* Any active or documented history of autoimmune disease, including but not limited to inflammatory bowel disease, celiac disease, Wegner syndrome, Hashimoto syndrome, systemic lupus erythematosus, scleroderma, sarcoidosis, or autoimmune hepatitis, within 3 years of the first dose of study treatment, except for the following:\n\n  * Type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders such as vitiligo, or alopecia not requiring systemic therapy, or conditions not expected to recur in the absence of an external trigger.\n  * Endocrinopathies where the participant is stable on hormone replacement therapy\n  * History of Hashimoto syndrome within 3 years of the first of study treatment that resolved to hypothyroidism alone",{"count":50,"type":20},46,[23],"This phase I trial tests the safety, side effects, best dose and effectiveness of AB801 in combination with chemotherapy and immunotherapy in treating patients with cholangiocarcinoma or pancreatic adenocarcinoma that may be removed by surgery (borderline resectable), that has spread to nearby tissue or lymph nodes (locally advanced), or that has spread from where it first started (primary site) to other places in the body (metastatic). AB801 is a drug designed to block a protein called AXL. AXL is found on the surface of certain cancer cells and plays an important role in helping tumors grow, spread to other parts of the body, and avoid the immune system. It is thought to contribute to resistance against common cancer treatments such as chemotherapy, radiation and immunotherapy. In many cancers, including cholangiocarcinoma and pancreatic adenocarcinoma, AXL is overactive and associated with worse outcomes. AB801 inhibits AXL which may make cancer cells more sensitive to chemotherapy and allow immune cells to better recognize and attack the tumor. Chemotherapy drugs, such as gemcitabine, cisplatin, oxaliplatin, irinotecan, leucovrin and fluorouracil, work in different ways to stop the growth of cancer cells either by killing the cells, by stopping them from dividing or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as durvalumab and zimberelimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving AB801 in combination with chemotherapy and immunotherapy may better treat patients with borderline resectable, locally advanced or metastatic cholangiocarcinoma or pancreatic adenocarcinoma.",[54,55,27,56,57,58,28,59],"Borderline Resectable Pancreatic Ductal Adenocarcinoma","Locally Advanced Cholangiocarcinoma","Metastatic Cholangiocarcinoma","Metastatic Pancreatic Adenocarcinoma","Stage II Pancreatic Cancer AJCC v8","Stage IV Pancreatic Cancer AJCC v8","NOT_YET_RECRUITING","2026-06-02",{"date":63,"type":33},"2026-06-04",{"date":65,"type":20},"2026-06-01",{"date":67,"type":20},"2028-06-01",{"name":69,"class":70},"Jonsson Comprehensive Cancer Center","OTHER",1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":71},"100638164","phase-1-64cu-dota-a2-scfv-fc2-dm-with-positron-emission-tomography-for-the-imaging-of-patients-with-locally-advanced-or-metastatic-psca-expressing-pancreatic-cancer-100638164","NCT07608627","64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic Cancer","A Phase 1 Clinical Trial of 64Cu-DOTA A2 scFv-Fc2 DM (64Cu-DOTA-A2DM) Positron Emission Tomography in Patients With Metastatic PSCA-Expressing Pancreatic Cancer","Inclusion Criteria:\n\n* Documented informed consent of the participant and\u002For legally authorized representative\n* Age: ≥ 18 years\n* Karnofsky \\> 70%\n* Advanced (locally or metastatic), histologically confirmed pancreatic adenocarcinoma\n* Evidence of locally advanced unresectable or metastatic disease demonstrated by an abnormal imaging scan (computed tomography \\[CT\\], magnetic resonance imaging \\[MRI\\], fludeoxyglucose \\[FDG\\]-PET) within 8 weeks prior to enrollment\n* No prior radiation therapy to target lesions\n* Hemoglobin ≥ 9g\u002FdL\n\n  * NOTE: Red blood cell transfusions are not permitted within 14 days of hemoglobin assessment unless cytopenia is secondary to disease involvement\n* Total bilirubin ≤ 1.5 X upper limit of normal (ULN) (unless has Gilbert's disease)\n* Aspartate aminotransferase (AST) ≤ 3.0 x ULN\n* Alanine aminotransferase (ALT) ≤ 3.0 x ULN\n* Serum creatinine \\\u003C 1.4 mg\u002FdL\n* Women of childbearing potential (WOCBP): negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* Agreement by females and males of childbearing potential\\* to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 months after the last dose of protocol therapy.\n\n  * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \\> 1 year (women only)\n\nExclusion Criteria:\n\n* Chemotherapy, radiation therapy, biological therapy, immunotherapy within 14 days or five half-lives (whichever is shorter for non-radiation therapy) prior to day 1 of protocol therapy\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent\n* Clinically significant uncontrolled illness\n* Other active malignancy. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n* Females only: Pregnant or breastfeeding\n* Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures\n* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics)",{"count":80,"type":20},15,[23],"This clinical trial tests the safety, side effects, best dose and feasibility of using 64Cu-DOTA A2 scFv-Fc2 DM with positron emission tomography for the imaging of patients with PSCA-expressing pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, 64Cu-DOTA A2 scFv-Fc2 DM. Because PSCA expressing pancreatic cancers take up 64Cu-DOTA A2 scFv-Fc2 DM it can be seen with PET. A PET scan is a procedure in which a small amount of radioactive glucose (sugar) is injected into a vein, and a scanner is used to make detailed, computerized pictures of areas inside the body where the glucose is taken up. Because cancer cells often take up more glucose than normal cells, the pictures can be used to find cancer cells in the body. Using 64Cu-DOTA A2 scFv-Fc2 DM with positron emission tomography may be a safe and feasible way to obtain diagnostic images of patients with locally advanced or metastatic PSCA-expressing pancreatic cancer.",[27,57,28,59],"2026-05-20",{"date":86,"type":33},"2026-05-27",{"date":88,"type":20},"2026-12-16",{"date":90,"type":20},"2028-07-14",{"name":92,"class":70},"City of Hope Medical Center",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":21,"phases":102,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":117},"100592861","phase-3-studying-chemotherapy-with-or-without-panitumumab-for-unresectable-locally-advanced-or-metastatic-pancreatic-cancer-without-kras-mutations-100592861","NCT06998940","Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations","Randomized Phase III Study of Second-Line Chemotherapy With or Without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma","Inclusion Criteria:\n\n* Participants must have a histologically or cytologically confirmed diagnosis of ductal adenocarcinoma of the pancreas\n* Participants must have previously documented KRAS wild type (i.e. absence of any KRAS mutation) and BRAF V600E wild type (i.e. absence of a BRAF V600E mutation) status determined by tumor tissue-based NGS assay. The testing must be done within a laboratory with Clinical Laboratory Improvement Act (CLIA), International Organization for Standardization (ISO)\u002FInternational Electrotechnical Commission (IEC), College of American Pathologists (CAP), or similar certification status\n\n  * NOTE: Blood-based next generation sequencing (NGS) assays, such as circulating tumor deoxyribonucleic acid (DNA) (ctDNA) or liquid biopsies, will not be accepted for meeting eligibility criteria\n* Participants must have documented unresectable and\u002For metastatic disease on CT or magnetic resonance imaging (MRI) imaging completed prior to randomization. Imaging must have been completed within 28 days prior to randomization for participants with measurable disease. CT scans or MRIs used to assess non-measurable disease must have been completed within 42 days prior to randomization. All disease must be assessed and documented on the Baseline Tumor Assessment Form (In calculating days of tests and measurements, the day a test or measurement is done is considered Day 0. Therefore, if a test is done on a Monday, the Monday 4 weeks later would be considered Day 28. This allows for efficient participant scheduling without exceeding the guidelines. If Day 14 or 28 falls on a weekend or holiday, the limit may be extended to the next working day)\n* Participants must not have known mutations in PTEN, NRAS, EGFR extracellular domain exons 1-16, no amplifications of HER2 and MET, and no gene fusions of RET, NTRK1, and ALK by tumor tissue-based NGS analysis\n\n  * NOTE: Participants who are not tested for these mutations are eligible if they have previously documented KRAS wild type (i.e. absence of any KRAS mutation) and BRAF V600E wild type (i.e. absence of a BRAF V600E mutation) status\n* Participants must not have known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and\u002For surgery and stable for at least 28 days before randomization (In calculating days of tests and measurements, the day a test or measurement is done is considered Day 0. Therefore, if a test is done on a Monday, the Monday 4 weeks later would be considered Day 28. This allows for efficient participant scheduling without exceeding the guidelines. If Day 14 or 28 falls on a weekend or holiday, the limit may be extended to the next working day).\n\n  * NOTE: Participants must be neurologically asymptomatic and without corticosteroid treatment at the time of enrollment\n* Participants must have received only one line of prior systemic cytotoxic chemotherapy for locally advanced or metastatic PDA, and have radiographically progressed, refractory, or intolerant to this therapy.\n\n  * Prior neoadjuvant or adjuvant therapy with 5-FU or gemcitabine-based chemotherapy counts as a line of therapy if the participant's disease progressed to locally advanced or metastatic disease within 6 months of completing treatment\n  * Participants with cancers harboring molecular alterations including microsatellite instability (MSI-high), elevated tumor mutational burden (TMB) (TMB ≥ 10 mut\u002FMb), and FGFR1-3, NRG1, and ROS fusions are allowed to have received an additional line of targeted therapy applicable to the respective molecular alterations at the treating investigators discretion.\n  * Prior maintenance therapy with Olaparib or Rucaparib for germline or somatic BRCA1\u002F2 or PALB2 mutations does not count as a line of therapy.\n* Participants must not have prior treatment with an anti-EGFR antibody (e.g., cetuximab or panitumumab)\n* Participants must not have prior treatment with an EGFR tyrosine kinase inhibitor (e.g., erlotinib)\n* Participants must not have received any pancreatic anticancer therapy (e.g., standard of care or investigational chemotherapy, molecularly targeted therapy, or radiation) within 14 days prior to randomization\n* Participants must not have a known contraindication to receiving chosen chemotherapy backbone at the planned doses in accordance with the local approved label\n* Participant must be ≥ 18 years old at the time of randomization\n* Participants must have Zubrod performance status of 0-2\n* Participants must have a complete medical history and physical exam within 28 days prior to randomization (In calculating days of tests and measurements, the day a test or measurement is done is considered Day 0. Therefore, if a test is done on a Monday, the Monday 4 weeks later would be considered Day 28. This allows for efficient participant scheduling without exceeding the guidelines. If Day 14 or 28 falls on a weekend or holiday, the limit may be extended to the next working day)\n* Absolute neutrophil count ≥ 1.0 x 10\\^3\u002FuL (within 28 days prior to randomization) (In calculating days of tests and measurements, the day a test or measurement is done is considered Day 0. Therefore, if a test is done on a Monday, the Monday 4 weeks later would be considered Day 28. This allows for efficient participant scheduling without exceeding the guidelines. If Day 14 or 28 falls on a weekend or holiday, the limit may be extended to the next working day)\n\n  * Note: Use of growth factor support (e.g., Granulocyte Colony-Stimulating Factor \\[G-CSF\\] or romiplostim \\[Nplate\\]) is permitted, and prior use does not constitute an exclusion criterion. Recent blood transfusions are also allowed\n* Hemoglobin ≥ 8 g\u002FdL (within 28 days prior to randomization) (In calculating days of tests and measurements, the day a test or measurement is done is considered Day 0. Therefore, if a test is done on a Monday, the Monday 4 weeks later would be considered Day 28. This allows for efficient participant scheduling without exceeding the guidelines. If Day 14 or 28 falls on a weekend or holiday, the limit may be extended to the next working day)\n\n  * Note: Use of growth factor support (e.g., G-CSF or romiplostim \\[Nplate\\]) is permitted, and prior use does not constitute an exclusion criterion. Recent blood transfusions are also allowed\n* Platelets ≥ 75 x 10\\^3\u002FuL (within 28 days prior to randomization) (In calculating days of tests and measurements, the day a test or measurement is done is considered Day 0. Therefore, if a test is done on a Monday, the Monday 4 weeks later would be considered Day 28. This allows for efficient participant scheduling without exceeding the guidelines. If Day 14 or 28 falls on a weekend or holiday, the limit may be extended to the next working day)\n\n  * Note: Use of growth factor support (e.g., G-CSF or romiplostim \\[Nplate\\]) is permitted, and prior use does not constitute an exclusion criterion. Recent blood transfusions are also allowed\n* Total bilirubin ≤ 1.5 x institutional upper limit of normal (IULN) (within 28 days prior to randomization) (In calculating days of tests and measurements, the day a test or measurement is done is considered Day 0. Therefore, if a test is done on a Monday, the Monday 4 weeks later would be considered Day 28. This allows for efficient participant scheduling without exceeding the guidelines. If Day 14 or 28 falls on a weekend or holiday, the limit may be extended to the next working day)\n* Aspartate aminotransferase (AST) ≤ 10 x upper limits of normal (ULN) (within 28 days prior to randomization) (In calculating days of tests and measurements, the day a test or measurement is done is considered Day 0. Therefore, if a test is done on a Monday, the Monday 4 weeks later would be considered Day 28. This allows for efficient participant scheduling without exceeding the guidelines. If Day 14 or 28 falls on a weekend or holiday, the limit may be extended to the next working day)\n* Participants must have a creatinine ≤ the IULN OR measured OR calculated creatinine clearance ≥ 30 mL\u002Fmin using the following Cockcroft-Gault Formula. This specimen must have been drawn and processed within 28 days prior to registration (In calculating days of tests and measurements, the day a test or measurement is done is considered Day 0. Therefore, if a test is done on a Monday, the Monday 4 weeks later would be considered Day 28. This allows for efficient participant scheduling without exceeding the guidelines. If Day 14 or 28 falls on a weekend or holiday, the limit may be extended to the next working day)\n* Participants with known history of human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at registration and have undetectable viral load test on the most recent test results obtained within 6 months prior to randomization\n* Participants with a known history of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load while on suppressive therapy on the most recent test results obtained within 6 months prior to randomization, if indicated\n* Participants with a known history of hepatitis C virus (HCV) infection must have been treated and cured. Participants currently being treated for HCV infection must have undetectable HCV viral load test on the most recent test results obtained within 6 months prior to randomization, if indicated\n* Participants must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the investigational regimen\n* Participants must not be pregnant or nursing (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped). Individuals who are of reproductive potential must have agreed to use an effective contraceptive method with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of \"reproductive potential.\" In addition to routine contraceptive methods, \"effective contraception\" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation\u002Focclusion, and vasectomy with testing showing no sperm in the semen\n* Participants must be offered the opportunity to participate in specimen banking\n* Participants who can complete patient reported outcomes (FACT-G and PRO-CTCAE) questionnaires in English or Spanish must be offered the opportunity to participate in the quality-of-life studies\n* Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines.\n\n  * For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations",{"count":101,"type":20},94,[103],"PHASE3","This phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil \\[5-FU\\] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine) versus standard chemotherapy alone in treating patients with KRAS wild type (WT) pancreatic ductal adenocarcinoma that cannot be removed by sugery (unresectable) or that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Panitumumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Chemotherapy drugs, such as nanoliposomal irinotecan, leucovorin, 5-FU, irinotecan, nab-paclitaxel and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding panitumumab to standard chemotherapy may be effective in treating patients with unresectable, locally advanced, or metastatic KRAS WT pancreatic ductal adenocarcinoma.",[27,57,28,59,106],"Unresectable Pancreatic Adenocarcinoma","2026-05-19",{"date":109,"type":33},"2026-05-22",{"date":111,"type":33},"2026-05-13",{"date":113,"type":20},"2030-12",{"name":115,"class":116},"SWOG Cancer Research Network","NETWORK",274,{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":21,"phases":127,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":133,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":141},"100567809","phase-1-ptm-101-in-pancreatic-ductal-adenocarcinoma-pdac-100567809","NCT06673017","PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)","A Phase Ib Dose Escalation\u002FDose Expansion Study of PTM-101 as an Adjunct to Neoadjuvant Therapy for Treatment Naïve, Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)","Inclusion Criteria:\n\n* Imaging consistent with primary borderline resectable or locally advanced PDAC. PDAC may be confirmed by histology\u002Fcytology either at study-mandated laparoscopy or by prior biopsy\u002Fcytology\n* Indicated for laparoscopy\n* No prior therapy of any kind for PDAC\n* Acceptable laboratory values\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2\n* Ability to provide informed consent\n* No symptomatic pancreatitis\n* No other active medical issues which would confound interpretation of safety monitoring, efficacy results or prevent the subject from study participation\n* Subjects with childbearing potential must agree to use adequate contraception throughout study participation\n\nExclusion Criteria:\n\n* Active non-pancreatic cancer that currently requires treatment or is being treated; diagnosis of another malignancy within the past 2 years. This criterion excludes a history of carcinoma in situ of the cervix, superficial non-melanoma skin cancers, or superficial bladder cancer that has been adequately treated, or stage 1 prostate cancer that does not require treatment or requires only treatment with luteinizing hormone-releasing hormone agonists or antagonists if initiated at least 30 days prior to screening). Other potentially indolent cancers may be considered.\n* Contraindications or allergies to paclitaxel, PLGA (poly(lactic-co-glycolic ) acid), or contraindications to implantation of PTM-101 or chemotherapies in protocol (e.g., FOLFIRINOX, gemcitabine, nab-paclitaxel)\n* Known history of human immunodeficiency virus (HIV) or active viral hepatitis\n* Active ongoing infection or autoimmune disease which may preclude laparoscopy, placement of PTM-101, administration of chemotherapy or surgical resection of pancreatic tumor\n* Inability to comply with activities and therapeutic interventions as outlined in the schedule of events\n* Currently enrolled in another investigational drug or device trial\n* Women who are pregnant or breastfeeding or who plan to become pregnant or breastfeed; men who plan to donate sperm or conceive a child\n* Any other medical or surgical conditions, including prior abdominal surgery, that would preclude safe laparoscopy or implantation in the opinion of the investigator",{"count":126,"type":20},26,[23],"This is a multi-center, non-randomized, single-arm, open-label, phase Ib, dose escalation\u002Fdose expansion study of PTM-101 when combined with neoadjuvant chemotherapy for the treatment of treatment-naïve subjects with borderline resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC).",[130,131,27,132],"Pancreatic Ductal Adenocarcinoma","Borderline Resectable Pancreatic Adenocarcinoma","Pancreatic Cancer",{"date":84,"type":33},{"date":135,"type":33},"2025-04-14",{"date":137,"type":20},"2028-06",{"name":139,"class":140},"PanTher Therapeutics","INDUSTRY",6,{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":21,"phases":151,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":163},"100598801","phase-2-evaluating-nalirifox-vs-modified-gemcitabine-nab-paclitaxel-and-cisplatin-in-patients-with-locally-advanced-and-metastatic-pancreatic-adenocarcinoma-100598801","NCT07076212","Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma","Phase II Study Evaluating NALIRIFOX Versus Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or female, aged ≥18 years\n* For females of reproductive potential: use of highly effective contraception for at least 1 month before screening and agreement to use such a method during study participation and for an additional 9 months after the end of the last dose of study medication administration\n* Female patients including WOCBP must test negative for pregnancy at the time of screening based on a urine or serum pregnancy test.\n* For males of reproductive potential: use of condoms or other methods to ensure effective contraception with a partner during the study and for 4 months after the last dose of study medication.\n* Histologically or cytologically confirmed locally advanced or metastatic PDAC that has not been previously treated\n* Radiographically confirmed measurable (per RECIST 1.1) locally advanced or metastatic PDAC per the National Comprehensive Cancer Network (NCCN) definition.\n* Inoperable status due to the presence of locally advanced, unresectable disease with or metastases.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Hematological, biochemical, and organ function inclusion criteria:\n\n  * Absolute neutrophil count (ANC) ≥1500\u002Fmm3 without the use of hemopoietic growth factors within 7 days before treatment\n  * Platelet count ≥100,000\u002Fmm3.\n  * International normalized ratio (INR) \\\u003C1.5 unless the patient is receiving anticoagulation therapy, in which case a therapeutic INR is acceptable. Anticoagulation therapy with low-molecular weight heparin or warfarin, whether medically indicated, is permitted.\n  * Adequate renal function, as evidenced by serum\u002Fplasma creatinine level \\\u003C1.6 mg\u002FdL\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Treatment with another investigational drug or other intervention within 30 days of protocol initiation.\n* Known hypersensitivity\u002Fallergic reaction to any of the components of the therapeutic agents in mGAP or NALIRIFOX.\n* Any other medical or social condition deemed by the investigator to be likely to interfere with a subject's ability to sign informed consent, cooperate, and participate in the study or who is likely to interfere with the interpretation of the results.\n* Unwilling or unable to comply with study procedures and\u002For study visits.\n* Uncontrolled, active infection\n* Histologic diagnosis other than adenocarcinoma.\n* Medical co-morbidities, that preclude major abdominal surgery",{"count":150,"type":20},52,[24],"This is a single-center, open-label, randomized Phase 2 trial to evaluate the efficacy of NALIRIFOX (Arm 1) vs mGAP (Arm 2) in previously untreated patients with locally advanced (unresectable) and metastatic pancreatic ductal adenocarcinoma (PDAC).",[57,27],"2026-05-04",{"date":156,"type":33},"2026-05-06",{"date":158,"type":33},"2026-04-02",{"date":160,"type":20},"2029-11",{"name":162,"class":70},"Medical University of South Carolina",2,{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":21,"phases":174,"briefSummary":175,"conditions":176,"keywords":179,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":194},"100605016","phase-1-a-phase-1-study-to-evaluate-safety-and-efficacy-of-xer-001-amifostine-for-nasoduodenal-delivery-in-combination-with-sterotactic-body-radiotherapy-for-treatment-in-patients-with-locally-advanced-pancreatic-cancer-100605016","NCT07157033","A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.","A Phase 1\u002F2a, Open Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of XER-001 (Amifostibe for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment of Locally-Advanced Pancreatic Adenocarcinoma","XER-001","Inclusion Criteria:\n\n1. Cytologic or biopsy confirmed adenocarcinoma of the pancreas\n2. Disease deemed amenable to definitive treatment with SBRT by being:\n\n   1. Locally-advanced and\u002For technically unresectable, as determined by a specialist pancreaticobiliary surgeon and as part of a multidisciplinary team review including of multiphase cross-sectional imaging, demonstrating: i. Greater than 180-degree tumor involvement of the superior mesenteric artery (SMA) ii. Greater than 180-degree tumor involvement of the celiac axis including major branches of the celiac axis that would render the tumor unresectable (e.g. common hepatic artery) iii. Tumor involvement of the first branch of the SMA that is not surgically reconstructible iv. Long segment involvement of the superior mesenteric vein\u002Fportal vein\u002Fhepatic artery that is not amenable to surgical reconstructible.\n   2. Potentially resectable anatomically but deemed not a surgical candidate after multidisciplinary review (such as unresectable due to comorbid conditions that render.\n\n      the risks of surgery prohibitive)\n   3. Potentially resectable but the patient elects to refuse surgery and prefers to pursue SBRT, and disease is deemed eligible for SBRT\n3. Primary tumor involvement abutment of the bowel is allowed, however bowel infiltration or invasion (identified endoscopically or by contrast enhanced imaging) is not allowed.\n4. No distant metastatic disease either prior to or following induction systemic therapy\n5. Completion of medically indicated first line systemic therapy, which may include but is not limited to regimens such as FOLFIRNOX, gemcitabine\u002Fabraxane, and similar regimens\n6. Patients must be able to understand and comply with any treatment related procedures for SBRT. including breath-hold techniques or tolerance of compression belt, or other motion management strategies for SBRT delivery.\n7. Age 18 years or older\n8. Eastern Cooperative Group (ECOG) performance status 0, 1, or 2\n9. Adequate hematologic function as indicated by:\n\n   1. Absolute neutrophil counts \\>\u002F= 1500\u002Fmm3\n   2. Hemaglobin \\>\u002F= 8.0 g\u002FdL\n   3. Plor current use of hepato atelet count \\>\u002F= 75,000\u002Fmm3\n10. No known liver disease or hepatic impairment, as well as no recent or current use of hepatotoxic drugs or substances that could compromise liver function unless a washout period has been completed. Adequate liver function as indicated by:\n\n    1. Total bilirubin \\\u003C\u002F= 1.5x upper limits of normal (per institutional laboratory reference standard)\n    2. Aspartate aminotransferase (AST) and alanine aminotranferase (ALT) \\\u003C\u002F= 2.5 upper limits of normal (per institutional reference standard)\n11. Baseline serum calcium level \\>\u002F= 8.4 mg\u002FdL\n12. No clinically significant history or presence of safety 12-lead ECG findings as judged by the investigator at screening and check-in(s), including each criterion as listed below:\n\n    1. Normal sinus rhythm (heart rate between 40 and 100 bpm)\n    2. QTcF interval \\\u003C\u002F= 470 msec\n    3. QRS interval \\\u003C\u002F= 110 msec\n    4. and PRS interval \\\u003C\u002F= 220 msec Repeat measurements may be performed at the discretion of the investigator or designee\n13. An understanding, ability, and willingness to fully comply with the protocol-defined schedule of assessments, procedures, and restrictions\n14. Must provide written informed consent prior to the initiation of any protocol specific procedures\n15. The effects of XER-001 on the developing human fetus are unknown. For this reason women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for at least six months following the last (fifth) day of radiotherapy on this study. Exceptions to this inclusion criterion are available to women who meet any of the following criteria:\n\n    * Postmenopausal (no menses in greater than or equal to 12 consecutive months or validated by follicle stimulating hormone \\[FSH\\] levels.\n    * History of hysterectomy or bilateral salpingo-oophorectomy\n    * Ovarian failure (FSH and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy)\n    * History of bilateral tubal ligation or another surgical sterilization procedure\n16. Approved methods of birth control are as follows: hormonal contraception (I.e. birth control pills, injection, implant, transdermal patch, vaginal ring), intrauterine device (IUD), tubal ligation or hysterectomy, subject\u002Fpartner post vasectomy, implantable or injectable contraceptives, and condoms with spermacide. Not engaging in sexual activity through six months following the last (fifth) day of radiotherapy on this study is an acceptable practice; however periodic abstinence, the rhytm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n\nFor male participants on this trial, contraception is required as above dusing the study and for at least three months following the last (fifth) day of radiotherapy on this study if the have partners who can become pregnant (woman of child-bearing potential). Similarly, male participants on this trial should not donate sperm during the study and for at lease three months following the last (fifth) day of radiotherapy on this study.\n\nExclusion Criteria:\n\n1. Prior radiotherapy to the upper abdomen with overlap of. the anticipated SBRT field\n2. Prior radiopharmaceutical therapy\n3. Prior surgical resection of the pancreatic tumor\n4. Uncontrolled or active gastric or duodenal ulcer disease within 30 days of enrollment\n5. Visable invasion of tumor into the bowel\u002Fstomach.duodenal lumen on endoscopic evaluation\n6. Residual or ongoing grade 3+ non-hemotological toxicity from chemotherapy other than alopecia\n7. Concurrent participation in another interventional clinical trial or use of another investigational agent within 30 days of study consent. Note that participation in non-interventional clinical trials (e.g. quality of life \\[QOL\\], imaging, etc) is not exclusionary\n8. Uncontrolled intercurrent illness including but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, renal failure, cardiac arrhythmia\n9. Patients with history of myocardial infarction or unstable angina within 6 months prior to study enrollment\n10. Patients with history of symptomatic or (CTCAE-defined) grade 3+ hypocalcemia\n11. Patients with history of hypoparathyroidism\n12. Patients with history of hypertension where medical providers deem that interruption of antihypertensive regimen for one week is deemed unsafe.\n13. Patients with systolic blood pressure (BP) \\\u003C 100 or diastolic BP \\\u003C 65 at screening or baseline\n14. History or presence of a disease, such as hepatic impairment or renal insufficiency, that could affect the absorption, distribution, metabolism, or elimination of the investigational product, tolerance to radiotherapy, or could affect clinical or laboratory assessments.\n\n    Patients with an estimated glomerular filtration rate of less than 30 mL per minute are excluded from the trial. Patients with total bilirubin greater than 2.5 mg\u002FdL are excluded from the trial unless patient has history of Gilbert's syndrome. In case of suspected or confirmed Gilbert's syndrome, bilirubin will be fractionated, and patients with direct bilirubin greater than 1.5 mg\u002FdL will be excluded from the trial.\n15. History of cardiac-related condition, which may include, but is not limited to, torsades de pointes, ventricular fibrillation, or ventricular tachycardia\n16. Presence or family history (parents and siblings) of congenital lqt syndrome or any premature history of myocardial infarction considered clinically significant by the investigator or designee\n17. History or presence of palpitations, unexplained syncope, shortness of breath or any other symptoms that may relate to cardiac arrhythmias\n18. Any ECG evidence of physiological variants predisposing to electrical instability (eg. frequent pre-ventricular systolic beats)\n19. Medical disorder that may require treatment during the study or make the subject unlikely to complete the study.\n20. Inability to fast for 3 hours prior to study drug administration\n21. Known history of active hepatitis B\u002FC or active human immunodeficiency virus (HIV) not on highly-active anti-retroviral therapy for a minimum of 30 days\n22. Donation or loss of more than 500 ml of whole blood within 30 days prior to screening\n23. Difficulty with venous access or unstable or unwilling to undergo catheter insertion\n24. Female subjects who are currently pregnant (have a positive pregnancy test), are lactating, or planning to breastfeed. Pregnant or breastfeeding women are excluded from this study because there is an unknown risk for adverse events in nursing infants secondary to treatment of the mother with amifostine, breastfeeding should be discontinued if the mother is treated with amifostine\n25. An employee of the sponsor or research site personnel directly affiliated with this study or their immediate family member defined as a spouse, parent, child, or sibling, whether biological or legally adopted\n26. A subject who, in the opinion of the investigator or designee, is considered unsuitable or unlikely to comply with the study protocol for any reason",{"count":173,"type":20},36,[23,24],"The purpose of this study is to assess the safety, tolerability and efficacy of XER-001 and identify a best dose for future studies.",[27,177,178],"Locally Advanced Pancreas Cancer","Locally Advanced Pancreatic Ductal Adenocarcinoma",[180,181,182,183,184],"locally advanced pancreatic cancer","pancreatic cancer","locally advanced pancreatic adenocarcinoma","SBRT","amifostine","2026-04-29",{"date":187,"type":33},"2026-05-01",{"date":189,"type":33},"2026-01-01",{"date":191,"type":20},"2034-07-31",{"name":193,"class":140},"Xerient Pharma",4,{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":21,"phases":203,"briefSummary":205,"conditions":206,"keywords":208,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":71},"100413619","early-phase-1-first-in-human-study-of-the-theranostic-pair-68gaga-dota-5g-and-177lulu-dota-abm-5g-in-pancreatic-cancer-100413619","NCT04665947","First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer","Inclusion Criteria:\n\n\\[68Ga\\]Ga DOTA-5G PET\u002FCT Inclusion Criteria:\n\n1. Ability to understand and willingness to sign a written informed consent document.\n2. Age 18 or more years\n3. Confirmed presence of locally advanced, unresectable or metastatic pancreatic adenocarcinoma (other pancreatic malignant histologies are excluded) with measurable disease per RECIST (version 1.1) (i.e. at least 1 lesion \\> 1 cm or lymph node \\> 1.5 cm in short axis)\n4. Participant must have documented tumor progression during or following at least one prior systemic regimen as established by CT or MRI scan within 28 days of enrollment\n5. Eastern Cooperative Oncology Group Performance Status ≤ 2\n6. Participant must have completed prior chemotherapy at least 2 weeks (washout period) prior to \\[68Ga\\]Ga DOTA-5G PET scan. Any clinically significant toxicity (with the exceptions of hair loss and sensory neuropathy) related to prior therapy resolved to Grade 1 or baseline.\n7. Hematologic parameters defined as:\n\n   1. Absolute neutrophil count (ANC) ≥ 1000 cells\u002Fmm3\n   2. Platelet count ≥ 100,000\u002Fmm3\n   3. Hemoglobin ≥ 8 g\u002FdL\n8. Blood chemistry levels defined as:\n\n   1. AST, ALT, alkaline phosphatase ≤ 5 times upper limit of normal (ULN)\n   2. Total bilirubin ≤ 2 times ULN\n   3. Creatinine ≤ 2 times ULN\n9. Anticipated life expectancy ≥ 3 months\n10. Able to remain motionless for up to 30-60 minutes per scan\n\n\\[177Lu\\]Lu DOTA-ABM-5G therapy Inclusion Criteria:\n\n1. Completion of entry into \\[68Ga\\]Ga DOTA-5G PET study and completion of scan\n2. The presence of at least one measurable disease by \\[68Ga\\]Ga DOTA-5G PET\u002FCT (SUVmax\\>2-fold above normal lung or liver)\n\nExclusion Criteria:\n\n* \\[68Ga\\]Ga DOTA-5G and \\[177Lu\\]Lu DOTA-ABM-5G therapy Exclusion Criteria:\n\n  1. Participant on any chemical anticoagulant including antiplatelet agents (excluding ASA)\n  2. Participants with Class 3 or 4 NYHA Congestive Heart Failure\n  3. Clinically significant bleeding within two weeks prior to trial entry (e.g. gastrointestinal bleeding, intracranial bleeding)\n  4. Pregnant or lactating women\n  5. Major surgery, defined as any surgical procedure that involves general anesthesia and a significant incision (i.e. larger than what is required for placement of a central venous access, percutaneous feeding tube, or biopsy) within 28 days prior to study day 1 or anticipated surgery within the subsequent 6 weeks\n  6. Has an additional active malignancy requiring therapy within the past 2 years\n  7. Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy\n  8. Psychiatric illness\u002Fsocial situations that would interfere with compliance with study requirements\n  9. Previous radiation therapy for the treatment of advanced or metastatic disease\n  10. Cannot undergo PET\u002FCT scanning because of weight limits (350 lbs)\n  11. INR\\>1.2; PTT\\>5 seconds above UNL",{"count":202,"type":20},30,[204],"EARLY_PHASE1","This is a Phase I, first-in-human study to evaluate the safety and efficacy of the \\[68Ga\\]Ga DOTA-5G and \\[177Lu\\]Lu DOTA-ABM-5G theranostic pair in patients with locally advanced or metastatic pancreatic adenocarcinoma (PDAC).",[207,27],"Metastatic Pancreatic Cancer",[209,210,211,212],"integrin","metastatic pancreatic cancer","PET","theranostic","2026-04-23",{"date":185,"type":33},{"date":216,"type":33},"2020-12-18",{"date":218,"type":20},"2027-12-31",{"name":220,"class":70},"University of California, Davis",{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":21,"phases":231,"briefSummary":232,"conditions":233,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":163},"100550930","phase-2-a-study-of-high-dose-radiation-therapy-for-locally-advanced-pancreatic-cancer-that-responded-to-initial-chemotherapy-treatment-100550930","NCT06453486","A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment","Ablative Radiation Therapy With High Dose Geometric Boost for Locally Advanced Pancreatic Cancer Patients Following Treatment Response Evaluation of Standard of Care Induction Chemotherapy (ABLATE): a Phase II Clinical Trial","ABLATE","Inclusion Criteria:\n\n* Have a histological or cytological diagnosis of LAPC.\n* Have pancreatic tumour \\\u003C8.0 cm in greatest axial dimension at the time of treatment planning but final determination of eligibility will be based upon satisfying the radiation normal tissue constraints.\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤1 (Karnofsky ≥70%).\n* Life expectancy of greater than 6 months, as judged by the investigator.\n* Patients must have had prior first-line chemotherapy for this cancer for at least 16 weeks without clinical or radiographic progression. There should be a washout of at least 2 weeks from first-line chemotherapy and start of therapy on clinical trial.\n* Ability to understand and willing to sign a written informed consent document.\n* Women must not be pregnant or breast-feeding. All females of child bearing potential must have a serum or urine pregnancy test to rule out pregnancy within 4 weeks prior to registration. All breastfeeding women should discontinue breastfeeding prior to study registration.\n\nExclusion Criteria:\n\n* Metastatic disease at the time of registration\n* Age\\\u003C18.\n* Patients who have had prior systemic treatment (chemotherapy or any other anti-cancer agent) in the metastatic setting.\n* Prior radiotherapy to the upper abdomen region that would result in overlap of RT volume for the current study.\n* Patients who are currently on anti-cancer treatment including chemotherapy.\n* Uncontrolled inter-current illness including, but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Pregnant and breastfeeding women.\n* Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures.\n* Individuals with a history of a different malignancy except if they have been disease-free for at least 2 years and are deemed by the investigator to be at low risk for recurrence. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.\n* Individuals with diseases precluding high dose ablative RT (e.g. scleroderma, gastric or bowel ulceration or perforation within the planned irradiated volume)\n* Patient should NOT be treated with MR-Linac if they have any contraindications for MRI, including presence of a heart pacemaker, (ferrous) metallic foreign bodies, and severe claustrophobia. Patients will be screened and excluded from the study if they have previous anaphylactic reactions to gadolinium and severe kidney disease (glomerular filtration rate \\\u003C 30mL\u002Fmin\u002F1.73m2) or acute kidney disease.",{"count":230,"type":20},43,[24],"The goal of this clinical trial is to test the effect of high-dose radiation therapy after initial chemotherapy in patients with locally advanced pancreatic cancer. The main question it aims to answer is:\n\n• For patients with locally advanced pancreatic cancer that responded to initial chemotherapy (stayed stable or decreased in size), will high-dose RT (radiation therapy) contribute to improving treatment outcomes, enhancing quality of life, or increasing overall survival rates?\n\nParticipants will:\n\n* Undergo an optional tumor biopsy.\n* Be treated with high dose radiation therapy.\n* Complete quality of life questionnaires.\n* Donate research blood samples.",[27],"2026-04-15",{"date":236,"type":33},"2026-04-16",{"date":238,"type":33},"2025-03-12",{"date":240,"type":20},"2030-04",{"name":242,"class":70},"University Health Network, Toronto",{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":21,"phases":253,"briefSummary":254,"conditions":255,"keywords":256,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":274},"100581462","phase-2-acoustic-cluster-therapy-act-with-chemotherapy-for-the-treatment-of-locally-advanced-pancreatic-cancer-100581462","NCT06850623","Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer","A Phase 2 Study to Investigate the Efficacy and Safety of Acoustic Cluster Therapy With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer","ENACT","Inclusion Criteria:\n\n* Not deemed suitable for primary curative surgery and have radiographic and pathological disease consistent with inoperable LAPC or borderline resectable pancreatic cancer.\n* Suitable to receive treatment with mFOLFIRINOX according to the Investigator's assessment.\n\nExclusion Criteria:\n\n• Any prior anti-cancer treatment for pancreatic cancer (e.g. chemotherapy, surgery, radiation). Palliative bypass procedure and bile duct stenting are allowed.",{"count":252,"type":20},25,[24],"The purpose of the study is to assess the efficacy and safety of Acoustic Cluster Therapy (ACT) when given in addition to chemotherapy for treatment of Locally Advanced Pancreatic Cancer.",[27],[181,257,258,259,260,180,261,262,263,264],"PS101","ultrasound","microbubbles","Pancreatic Ductal Carcinoma","first line treatment","chemotherapy","Acoustic Cluster Therapy","mFOLFIRINOX","2026-03-30",{"date":267,"type":33},"2026-04-03",{"date":269,"type":33},"2025-06-19",{"date":271,"type":20},"2027-07-15",{"name":273,"class":140},"EXACT Therapeutics AS",10,{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":21,"phases":284,"briefSummary":285,"conditions":286,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":71},"100502654","phase-2-neoadjuvant-chemotherapy-for-borderline-resectable-and-locally-advanced-pancreatic-adenocarcinoma-100502654","NCT05825066","Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma","Sequential Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma","Inclusion Criteria:\n\n* Patients must have histologically or cytologically proven adenocarcinoma of the pancreas. Patients with mixed tumor with predominant adenocarcinoma pathology can be enrolled\n* Patients with borderline resectable or locally advanced pancreatic adenocarcinoma as assessed per National Comprehensive Cancer Network (NCCN) guidelines (either pancreatic head, neck, uncinate process, or body\u002Ftail) or institutional multidisciplinary consensus\n* Age 18 or above\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1\n* Patients must have organ and marrow function as defined below:\n\nHemoglobin\\* ≥8 g\u002FdL Absolute neutrophil count ≥1,500\u002FmcL Platelets\\* ≥100,000\u002FmcL Total bilirubin\\* ≤1.5 X institutional upper limit of normal AST(SGOT)\u002FALT(SGPT) \\\u003C2.5 X institutional upper limit of normal Creatinine ≤1.5 X institutional upper limit of normal or CrCL\\>50\n\n* It is acceptable to transfuse packed red blood cells (PRBC) and platelets at the time of enrollment to meet the eligibility criteria.\n* If obstructive jaundice is present, consider ursodiol or a biliary drainage procedure. If the total bilirubin can be reduced or kept to less than or equal to 3 mg\u002FdL, then this inclusion criteria is met.\n\n  * Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST v1.1).\n  * Ability to understand and the willingness to sign an IRB-approved informed consent document (either directly or via a legally authorized representative)\n\nExclusion Criteria:\n\n* Patients who have had prior chemotherapy with gemcitabine and\u002For nab-paclitaxel or FOLFIRINOX for pancreatic cancer\n* Patients receiving any other investigational anti-neoplastic agents\n* History of malignancy in last 3 years except cervical cancer in situ, adequately treated basal cell or squamous cell carcinoma of skin or treated low risk prostate cancer, who are considered to be eligible\n* Patients with active and uncontrolled bacterial, viral or fungal infection requiring systemic therapy. Patients can be reevaluated for the study if the infection is deemed to be under control and the systemic therapy for the infection is completed\n* Uncontrolled intercurrent illness including, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements or compromise the patient's safety\n* Patients with known diagnosis of interstitial lung disease, sarcoidosis, pulmonary fibrosis, or pneumonitis requiring oxygen supplementation. Those that do not require oxygen supplementation are eligible.\n* Patients who have undergone surgery, other than diagnostic or minor procedures, within 4 weeks prior to the initiation of study treatment\n* Patients who are pregnant or breastfeeding",{"count":283,"type":20},64,[24],"The objective of this research is to find out what effects (good and bad), the sequence of Gemcitabine - Abraxane (nab-Paclitaxel) followed by mFOLFIRINOX, the standard chemotherapy for pancreatic cancer, has on participants and their condition. Gemcitabine - Abraxane (nab-Paclitaxel) and mFOLFIRINOX has been approved by the US Food and Drug Administration (FDA) as first line treatment for advanced pancreatic cancer. The sequence of Gemcitabine - Abraxane (nab-Paclitaxel) followed by mFOLFIRINOX has not been approved by the FDA for treatment of pancreatic cancer.",[287,131,27],"Pancreas Adenocarcinoma","2026-03-23",{"date":290,"type":33},"2026-03-25",{"date":292,"type":33},"2023-08-01",{"date":294,"type":20},"2028-07",{"name":296,"class":70},"Wake Forest University Health Sciences",{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":303,"eligibilityCriteria":304,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":305,"targetDuration":4,"studyType":21,"phases":307,"briefSummary":308,"conditions":309,"keywords":311,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":328},"100582267","phase-3-the-effect-of-kinisoquin-on-thromboembolic-events-in-patients-with-metastatic-or-locally-advanced-pancreatic-cancer-100582267","NCT06861088","The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer","A Randomized, Placebo-Controlled, Double-Blind Phase 3 Trial Comparing, Relative to Placebo, the Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer (CATIQ P3)","CATIQ P3","Inclusion Criteria:\n\n1. Participants must have histological or cytological confirmed pancreatic adenocarcinoma malignancy that is metastatic (including recurrent with distant metastases) or locally advanced.\n2. Receiving first line chemotherapy (within 45 days of first dose of study drug) Note: subjects must be either initiating first systemic cancer therapy regimen following initial diagnosis or initiating first cycle of chemotherapy for disease recurrence.\n3. Minimum age 18 years.\n4. Life expectancy of greater than 4 months.\n5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.\n6. Participants must have preserved organ and marrow function as defined by:\n\n   * Platelet count ≥ 100,000\u002FmcL.\n   * Prothrombin time (PT) and partial thromboplastin time (PTT) ≤ 1.5x institutional upper limit of normal (ULN).\n   * Total bilirubin ≤ 3x ULN without liver metastases and \\\u003C 5x ULN in presence of liver metastases.\n   * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3x ULN without liver metastases and \\\u003C 5x ULN in the presence of liver metastases\n   * Estimated creatinine clearance (CrCl \\> 30 mL\u002Fmin).\n7. Willingness of women of child-bearing potential and men to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation until at least 4 weeks after study completion.\n8. Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Participants with known brain metastases\n2. Prior history of documented thromboembolic event within the last 12 months (excluding central line associated events whereby patients completed anticoagulation)\n3. Active bleeding or high risk for bleeding (e.g. known acute gastrointestinal ulcer)\n4. History of significant hemorrhage (requiring hospitalization or transfusion) outside of a surgical setting within the last 24 months\n5. Familial bleeding diathesis\n6. Known diagnosis of disseminated intravascular coagulation (DIC)\n7. Currently receiving anticoagulant therapy\n8. Current daily use of aspirin (\\> 100mg daily), Clopidogrel (Plavix), cilostazol (Pletal), aspirin-dipyridamole (Aggrenox) (within 10 days) or considered to use regular use of higher doses of non-steroidal anti-inflammatory agents as determined by the treating physician (e.g. ibuprofen \\> 800mg daily or equivalent)\n9. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n10. Known intolerance to the active ingredient of Kinisoquin™, isoquercetin, nicotinic acid, or ascorbic acid (including known G6PD deficiency)\n11. Females of child-bearing potential who are lactating, have a positive pregnancy test at Screening, or are unwilling to use acceptable contraception prior to study entry and for the duration of study participation until at least 4 weeks after study completion.\n12. Participation in other clinical trials The study is open to any individual who has a metastatic or locally advanced pancreatic adenocarcinoma malignancy without discrimination based on race, religion, political affiliation, or other criteria.",{"count":306,"type":20},480,[103],"The aim of this Phase 3 study is to evaluate the efficacy of Kinisoquin™ as compared to the placebo in prevention of thromboembolic events in patients with metastatic or locally advanced pancreatic cancer.",[310,207,27],"Venous Thromboembolism",[207,312,313,314,315,316,317,318],"Pancreatic Adenocarcinoma","Thromboembolism","Cancer-associated Thrombosis","Deep Vein Thrombosis","Pulmonary Embolism","Chemotherapy-associated VTE","Locally Advanced Pancreatic Cancer","2026-01-29",{"date":321,"type":33},"2026-02-02",{"date":323,"type":33},"2025-12-19",{"date":325,"type":20},"2029-10-31",{"name":327,"class":140},"Quercis Pharma AG",3,{"id":330,"slug":331,"hasResults":11,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":336,"targetDuration":4,"studyType":21,"phases":338,"briefSummary":340,"conditions":341,"keywords":344,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":71},"100491480","stereotactic-body-radiation-and-tumor-treating-fields-for-locally-advanced-pancreas-cancer-100491480","NCT05679674","Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer","Phase 2 Trial of Ablative MRI-guided Stereotactic Body Radiation Therapy and Tumor Treating Fields for Locally Advanced Pancreas Cancer","Inclusion Criteria:\n\n* Histologically or cytologically confirmed locally advanced adenocarcinoma of the pancreas. Locally advanced pancreas cancer as per National Comprehensive Cancer Network (NCCN) Guidelines.\n* Regional lymph node involvement is permitted if able to be treated with radiation therapy.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* At least 3 months of prior FOLFIRINOX, modified FOLFIRINOX, and\u002For gemcitabine\u002Fnab-paclitaxel delivered for pancreas cancer without evidence of distant progression on restaging radiographic studies.\n* Carbohydrate antigen 19-9 (CA 19-9) ≤500 U\u002FmL on most recent assessment prior to study enrollment.\n* Adequate normal organ and marrow function as defined below:\n\n  i. Hemoglobin ≥8.0 g\u002FdL that may be achieved with transfusion ii. Absolute neutrophil count (ANC) ≥1500 per mm\\^3 iii. Platelet count ≥60,000 per mm\\^3 iv. Serum bilirubin ≤1.5 x institutional upper limit of normal (ULN) v. AST (SGOT)\u002FALT (SGPT) ≤3 x institutional ULN\n* People of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a participant become pregnant or suspect they are pregnant while participating in this study, they must inform the treating physician immediately.\n* Able to operate the tumor treating field (NovoTTF-100L) system independently or with assistance.\n* All participants must sign written informed consent.\n\nExclusion Criteria:\n\n* Distant metastasis from pancreas cancer.\n* Contraindication to having a magnetic resonance imaging (MRI) scan.\n* Prior abdominal radiation therapy.\n* History of any primary malignancy with the exception of:\n\n  1. Malignancy treated with curative intent and with no known active disease for at least 3 years before enrollment on this study.\n  2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.\n  3. Adequately treated carcinoma in situ without evidence of disease (i.e., cervical carcinoma in situ; superficial bladder cancer).\n* Any unresolved toxicity (Common Terminology Criteria for Adverse Events version 5.0 \\> grade 2) from previous anti-cancer therapy. Participants with irreversible toxicity that is not reasonably expected to worsen by treatment on this study are permitted to enroll on this study.\n* History of inflammatory bowel disease (i.e., Crohn's disease, ulcerative colitis).\n* Any condition in the opinion of the investigator that would interfere with evaluation of study treatment or interpretation of patient safety or study results.\n* Participants who are pregnant or breastfeeding. Patients with an electrical implantable device in the torso. Examples of electrical implanted medical devices include spinal cord stimulators, vagus nerve stimulators, pacemakers, and defibrillators.\n* History of significant uncontrolled cardiovascular disease. Significant cardiac disease includes second\u002Fthird degree heart block; significant ischemic heart disease; poorly controlled hypertension; congestive heart failure of the New York Heart Association (NYHA) Class II or worse.\n* History of arrhythmia that is symptomatic or requires treatment. Patients with atrial fibrillation or flutter controlled by medication are not excluded from participation in the trial.\n* Known allergy to medical adhesives or conductive hydrogel \\[gel used on electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes\\].",{"count":337,"type":20},48,[339],"NA","The purpose of this clinical trial is to determine whether using chemotherapy followed by stereotactic ablative body radiation therapy (SABR) and tumor treating fields (TTF) will slow tumor growth in people with locally advanced pancreas cancer. All participants will receive SABR therapy once per day for five days and use the TTF system for at least 18 hours per day starting on the first day of SABR until the tumor progresses or severe toxicity develops.",[342,343,27],"Pancreas Cancer","Locally Advanced",[345,346,262],"tumor treating fields","stereotactic ablative body radiation","2026-01-08",{"date":349,"type":33},"2026-01-12",{"date":351,"type":33},"2023-09-21",{"date":353,"type":20},"2027-06",{"name":355,"class":70},"Baptist Health South Florida",{"id":357,"slug":358,"hasResults":11,"nctId":359,"briefTitle":360,"officialTitle":361,"acronym":362,"eligibilityCriteria":363,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":364,"targetDuration":4,"studyType":21,"phases":366,"briefSummary":367,"conditions":368,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":71},"100582295","phase-1-phase-iiia-study-rr001-administered-following-chemotherapy-cycles-for-patients-with-locally-advanced-pancreatic-carcinoma-100582295","NCT06861452","Phase I\u002FIIa Study: RR001 Administered Following Chemotherapy Cycles for Patients With Locally Advanced Pancreatic Carcinoma","RR001 in Combination With Chemotherapy for Patients With Locally Advanced Pancreatic Adenocarcinoma: Open-label, Non-randomized Dose Escalation Phase I\u002FIIa Study","SNIPER","Inclusion Criteria:\n\n* Patients with confirmed pancreatic ductal adenocarcinoma classified as locally advanced pancreatic adenocarcinoma (LPAC)\n* Patients with no evidence of peritoneal or hematogenous metastasis\n* Patients classified as non-resectable locally advanced pancreatic carcinoma (LAPC) based on imaging (TC and NMR), on multidisciplinary staff evaluation by at least an oncologist, radiologist and a qualified digestive surgeon and accounting for AJCC\u002FUICC TNM and clinical staging\n* Measurable tumor according RECIST criteria v 1.1\n* Low tumor burden with at least one lesion equal\u002Fless than 3,5 cm that is suitable for US guided injection (and needle biopsy).\n* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2\n* Patients must be eligible for chemotherapy treatment (based on standard of care)\n* Patient older than 18 years of age\n* Adequate hepatic and kidney function\u002FSafe hematologic profile\n* Negative serum pregnancy test for females of childbearing potential within days of starting treatment\n* Willingness and ability to comply with the scheduled visits, treatment plan, imaging procedures, laboratory tests and other study procedures, including lipoaspirate collection (liposuction)\n\nExclusion Criteria:\n\n* Patient with pancreatic cystic tumor or pancreatic pseudocyst\n* Patient with pancreatic tumor different from adenocarcinoma (endocrine, metastases)\n* Patients with unknown stage or recurrent pancreatic cancer\n* Patients with immunosuppression or susceptibility to viral infection\n* Patients with HIV, hepatitis B, hepatitis C, HTLV-I\u002FII, Treponema Pallidum infections\n* Patients with liver cirrhosis or other documented liver diseases\n* Patient contraindication to use chemotherapy treatments\n* Previous of radiotherapy and chemotherapy for PDAC\n* Previous hematopoietic stem cell or organ transplantation\n* Irreversible cardiac arrhythmias requiring permanent medication\n* Heart insufficiency (\\> grade II, New York Heart Association NYHA criteria)\n* History within the last year of acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris\n* Uncontrolled hypertension\n* Other malignancies within the past 2 years (not including basal cell carcinoma of the skin, prostate cancer or in situ cervix carcinoma, in situ melanoma).\n* Active autoimmune disease\n* Use of any investigational agents within 21 days from the administration of study treatment\n* Patient has had major open surgery prior to the administration of study treatment\n* Uncontrolled intercurrent illness including but not limited to psychiatric illness\u002Fsocial situations that in the opinion of the Investigator would compromise compliance of study requirements or put the patient at unacceptable risk\n* Suspected or known allergy or hypersensitivity to fluoroquinolones including but not limited to ciprofloxacin\n* Suspected or known allergy or hypersensitivity to protamine sulfate or protamine containing products. Including but not limited to patients who have previously undergone procedures such as coronary angioplasty or cardio-pulmonary bypass, which may involve the use of protamine, diabetics who have been treated with protamine insulin, patients allergic to fish, and men who have undergone a vasectomy or are infertile and may have antibodies to protamine",{"count":365,"type":20},9,[23,24],"RR001, a cell-based gene therapy administered following chemotherapy cycles for the treatment of patients with locally advanced pancreatic cancer. Phase I \u002FIIa clinical trial (open label and non-randomized) to test the effects (safety \\& efficacy) of increasing doses of RR001",[27],{"date":370,"type":33},"2025-12-26",{"date":372,"type":33},"2025-06-25",{"date":374,"type":20},"2027-01-29",{"name":376,"class":140},"EIR Biotherapies s.r.l.",{"id":378,"slug":379,"hasResults":11,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":383,"eligibilityCriteria":384,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":385,"enrollmentInfo":386,"targetDuration":4,"studyType":21,"phases":388,"briefSummary":389,"conditions":390,"keywords":391,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":395,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":401,"locationsCount":365},"100406325","phase-2-sequential-treatment-with-gembrax-and-then-folfirinox-followed-by-stereotactic-mri-guided-radiotherapy-in-patients-with-locally-advanced-pancreatic-cancer-100406325","NCT04570943","Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer","Phase II Study to Assess the Interest of a Sequential Treatment With Gemcitabine\u002FNab-paclitaxel (GEMBRAX) and Then FOLFIRINOX Followed by Stereotactic Magnetic Resonance-guided Adaptive Radiotherapy in Patients With Locally Advanced Pancreatic Cancer","GABRINOX-ART","Inclusion Criteria:\n\n1. Patient aged from 18 to 75 years at the date of signature of the consent form\n2. Histologically or cytologically proven pancreatic adenocarcinoma\n3. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1\n4. Non-resectable tumour according to the National Comprehensive Cancer Network (NCCN) 1.2015 recommendations after external review of imaging data by multidisciplinary experts.\n5. Non-metastatic cancer confirmed by thorax-abdomen-pelvis computerized tomography (CT) scan and liver MRI\n6. SMART feasibility confirmed by centralized review\n7. Uracilemia \\\u003C 16 ng\u002Fml\n8. Hematological assessment within 14 days before inclusion, defined by:\n\n   * Neutrophils ≥ 2 000\u002Fmm3 (2 × 109\u002FL);\n   * Platelets ≥ 100 000\u002Fmm3 (100 × 109\u002FL);\n   * Hemoglobin ≥ 9 g\u002Fdl\n9. Liver function (within 14 days before inclusion) defined by:\n\n   * ASpartate Transaminase (AST) and ALanine Transaminase (ALT) ≤ 2.5 x Upper Limit of Normal (ULN);\n   * Total bilirubin ≤ 1.5 x ULN. Patients with a metallic biliary prosthesis due to biliary obstruction caused by the cancer may be included, if: a CT scan with injection of contrast medium and thin pancreas sections was performed before placing the biliary prosthesis, the bilirubin level after prosthesis fitting decreased to ≤20 mg\u002FL (≤34 μmol\u002FL), and in the absence of cholangitis.\n10. Creatininaemia within the reference limits, or calculated clearance ≥50 ml\u002Fmin for patients with a serum creatinine value above or below the reference values (clearance calculated using the Chronic Kidney Disease EPIdemiology collaboration (CKDEPI formula).\n11. Serum calcium AND magnesium AND potassium ≥ Lower Limit Normal (LLN and ≤ 1.2 x Upper Limit Normal (ULN)\n12. Cancer Antigen (CA 19.9) \\\u003C500 IU\u002FmL (without cholestasis). Patients with CA 19.9 between 500 IU\u002FmL and 1000 IU\u002FmL can be included if the Positron Emission Tomography (PET) scan and peritoneal MRI (optional) do not detect any distant fixation, indicative of metastasis. Patients with CA 19.9 ≥ 1000 IU\u002FmL cannot be included.\n13. Sexually active patients must use a contraceptive method considered adequate and suitable by the investigator during the entire period of administration of the study treatment and up to 6 months after the treatment end, for female and male patients.\n14. Signature of the consent form before any study-specific procedure.\n15. Covered by the French health insurance.\n\nExclusion Criteria:\n\n1. Any previous treatment for pancreatic cancer (e.g. chemotherapy, radiotherapy, surgery, targeted therapy, experimental therapy)\n2. Gilbert's syndrome or homozygous Uridine DiPhosphate Glucuronosyl Transferase 1 A1 (UGT1A1 \\* 28)\n3. Other concomitant cancer or history of cancer, except for treated in situ cancer of the cervix , basal cell or squamous cell carcinoma, superficial bladder tumour (Ta, Tis, and T1), or good-prognosis tumour cured without chemotherapy and without signs of disease in the 3 years before inclusion\n4. Prior radiotherapy likely to overlap with the planned study radiotherapy area (e.g. previous abdominal irradiation).\n5. Patients with high cardiovascular risk, including, but not limited to, coronary stent or myocardial infarction in the past 6 months.\n6. Peripheral neuropathy ≥ grade 2\n7. ECG with QTcorrected (QTc) interval longer than 450 ms for men and longer than 470 ms for women\n8. Contraindication to MRI and MRI-guided radiotherapy\n9. History of chronic inflammatory disease of the colon or rectum\n10. Any other concomitant and not controlled serious illness or disturbance that may interfere with the patient's participation in the study and safety during the study (e.g. severe liver, kidney, lung, metabolic, or psychiatric disorder)\n11. Intolerance or allergy to one of the study drugs (gemcitabine, Nab-paclitaxel, oxaliplatin, irinotecan, 5-FU) or to one of their excipients (e.g. fructose) listed in the Contraindications or Warnings sections and Special precautions of the Summary of Product Characteristics (SmPC) or prescription information\n12. Legal incapacity (patient under guardianship or wardship)\n13. Pregnant or breastfeeding woman. Fertile women must have a negative pregnancy test (serum β-hCG) performed 72 hours before inclusion\n14. Patient using vitamin K antagonists (Coumadin…) (possible modification of the treatment before inclusion)\n15. Active and uncontrolled bacterial or fungal infection that requires systemic treatment.\n16. Know active HIV infection\n17. History of peripheral arterial disease (e.g. lameness, Buerger's disease).\n18. Patient who received a attenuated live vaccine in the 10 days before inclusion\n19. Patient with history of pulmonary fibrosis or interstitial pneumonia.\n20. Inability to attend the follow-up visits due to geographic, social or mental reasons.\n21. Participation in another clinical study with a research product during the last 30 days before inclusion.","75 Years",{"count":387,"type":20},103,[24],"The aim of this study is to demonstrate the efficacy of intensified and sequential chemotherapy (Gabrinox) comprising Gembrax regimen (Gemcitabine-Abraxane) followed by the Folfirinox regimen (5FU, Oxaliplatin and Irinotecan) in patients with locally advanced pancreatic adenocarcinoma.\n\nThe study will also demonstrate the feasibility of combining this intensified chemotherapy with MRI-guided stereotactic radiotherapy in non-progressive patients after the chemotherapy by Gabrinox regimen.",[27],[392,393],"Pancreatic","cancer","2025-11-28",{"date":396,"type":33},"2025-12-05",{"date":398,"type":33},"2021-06-16",{"date":400,"type":20},"2030-06",{"name":402,"class":70},"Institut du Cancer de Montpellier - Val d'Aurelle",{"id":404,"slug":405,"hasResults":11,"nctId":406,"briefTitle":407,"officialTitle":408,"acronym":409,"eligibilityCriteria":410,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":411,"targetDuration":4,"studyType":413,"phases":4,"briefSummary":414,"conditions":415,"keywords":416,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":430,"locationsCount":71},"100611521","surgery-for-locally-unresectable-pancreatic-cancer-100611521","NCT07241663","Surgery for Locally Unresectable Pancreatic Cancer","Conversion Surgery for Locally Unresectable Pancreatic Cancer - International Multi-center Observational Trial (ROBIN= suRgery for lOcally unresectaBle pancreatIc Cancer)","ROBIN","Inclusion Criteria:\n\n* Patients older than 18 years\n* Patients able to give informed consent\n* Histologically confirmed pancreatic adenocarcinoma\n* LAPC stage according to NCCN10 at diagnosis (Figure 1)\n* Received at least 4 months of induction chemotherapy\n* RECIST 1.1 stable disease (SD) or partial response (PR) after induction therapy\n* Patient considered eligible for radical resection by local MDT\n\nExclusion Criteria:\n\n* Informed consent withdrawal\n* Presence of tumor characteristics precluding surgery\n* Presence of patient significant comorbidities precluding surgery\n* Unavailable pre-induction therapy abdominal imaging\n* Pathological confirmation of any tumor different from PDAC",{"count":412,"type":20},150,"OBSERVATIONAL","Pancreatic cancer is a severe disease often diagnosed at an advanced stage, when surgery is not possible. New chemotherapy treatments can sometimes shrink the tumor and make surgery an option. This study aims to understand if surgery after such treatments can improve survival and quality of life in selected patients treated at expert centers.",[27],[417,418,419,420,421,422],"Pancreatic cancer","Coversion Surgery Pancreatic Cancer","Quality of Life","Locally advanced PDAC","Unresectable Pancreatic Cancer","Neoadjuvant therapy for pancreatic cancer","2025-11-21",{"date":425,"type":33},"2025-11-26",{"date":427,"type":33},"2025-01-01",{"date":429,"type":20},"2028-12-31",{"name":431,"class":70},"Azienda Ospedaliera di Padova",{"id":433,"slug":434,"hasResults":11,"nctId":435,"briefTitle":436,"officialTitle":436,"acronym":437,"eligibilityCriteria":438,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":439,"targetDuration":4,"studyType":21,"phases":441,"briefSummary":442,"conditions":443,"keywords":444,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":454},"100600405","phase-2-evaluation-of-the-stereotactic-mr-guided-adaptive-radiotherapy-for-locally-advanced-pancreatic-cancers-100600405","NCT07097064","Evaluation of the Stereotactic MR-guided Adaptive Radiotherapy for Locally Advanced Pancreatic Cancers","RAIPANC","Inclusion Criteria:\n\n* Histologically proven pancreatic adenocarcinoma ;\n* Age ≥ 18 years ;\n* WHO score 0-1 ;\n* Locally advanced according to NCCN 1.2015 recommendations;\n* Non-metastatic after TAP scan and MRI of the liver ;\n* CA 19.9 \\\u003C 1000 IU\u002FmL ;\n* Completion of at least 4 cycles of induction chemotherapy (Folfirinox and\u002For Gemzar-Abraxane) with a maximum of 8 courses ;\n* Women of childbearing potential must have a pregnancy blood test within a maximum of 7 days before starting the study treatment. A negative result must be documented before study treatment is started. Women without reproductive potential are postmenopausal women or women who have undergone permanent sterilisation (e.g. tubal occlusion, hysterectomy, bilateral salpingectomy) ;\n* Effective contraception for women of childbearing age ;\n* Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures ;\n* Patient has given informed, written and express consent ;\n* Patient affiliated to a French health insurance scheme.\n\nExclusion Criteria:\n\n* Other concomitant cancer or history of cancer, with the exception of treated cervical cancer in situ, basal or squamous cell skin carcinoma, superficial bladder tumour (Ta, Tis, and T1) or a tumour with a good prognosis treated curatively without chemotherapy and without evidence of disease in the 3 years prior to inclusion ;\n* History of radiotherapy with a foreseeable overlap with the radiotherapy treatment under study (history of abdominal irradiation) ;\n* Contraindication to MRI and MRI-guided radiotherapy (claustrophobia, presence of metallic elements etc...) ;\n* History of chronic inflammatory disease of the colon or rectum ;\n* Women who are pregnant, parturient or breastfeeding ;\n* Any other serious concomitant and unbalanced disease or disorder that may interfere with the patient's participation in the study and his\u002Fher safety during the study (e.g. severe hepatic, renal, pulmonary, metabolic, or psychiatric disorders) ;\n* Legal incapacity (patient under curatorship or guardianship) ;\n* History of severe and unexpected reactions to treatment containing a fluoropyrimidine ;\n* Hypersensitivity to capecitabine, to used excipients or to fluorouracil ;\n* Known complete deficiency of dihydropyrimidine dehydrogenase (DPD) ;\n* In patients with severe leukopenia, neutropenia or thrombocytopenia ;\n* In patients with severe hepatic insufficiency ;\n* Patients with severe renal insufficiency (creatinine clearance less than 30 mL\u002Fmin) ;\n* Recent or concomitant treatment with brivudine.",{"count":440,"type":20},160,[24],"Pancreatic cancer is on the rise, and is set to become the 2nd leading cause of cancer deaths by 2030. Its prognosis is very poor, with a 5-year survival rate of just 5.5%. Curative surgery with chemotherapy improves survival, but only 20% of patients are eligible. For locally advanced forms, radiotherapy, notably in the form of MRI-guided adaptive stereotactic radiotherapy (SMART), is showing promising results in terms of survival and local control, but still requires prospective validation.",[27],[312,445],"adaptative radiotherapy","2025-07-30",{"date":448,"type":33},"2025-07-31",{"date":450,"type":20},"2025-09",{"date":452,"type":20},"2033-09",{"name":402,"class":70},17,{"id":456,"slug":457,"hasResults":11,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":461,"eligibilityCriteria":462,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":463,"enrollmentInfo":464,"targetDuration":4,"studyType":21,"phases":466,"briefSummary":467,"conditions":468,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":474,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":480,"locationsCount":71},"100571004","phase-3-standard-or-prolonged-neoadjuvant-chemotherapy-before-surgery-for-brlapc-100571004","NCT06714604","Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR\u002FLAPC","Standard Versus Prolonged Neoadjuvant (Conversion) Chemotherapy to Prolong Survival of Patients With Borderline and Locally Advanced Pancreatic Cancer: a Phase III Randomized Controlled","ADVANTAGE","Inclusion Criteria:\n\n* Borderline or locally advanced pancreatic adenocarcinoma at diagnosis according to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines, version 1.2022\n* Histo- or cytologically confirmed adenocarcinoma (preferably EUS-guided)\n* T1-4, Nx, M0 according to AJCC 8th edition\n* ECOG 0-1 and considered fit for the planned chemotherapy at the local hospital and surgery at the two national centers for BR\u002FLAPC\n* Written informed patient consent\n\nExclusion Criteria:\n\n* Co-morbidity precluding pancreatic surgery or chemotherapy\n* Contraindications to any of the drugs in the proposed treatment regimens\n* ECOG ≥2\n* Neuropathy ≥ grade 2 according to Common Terminology Criteria for Adverse Events (CTCAE), version 6\n* Granulocyte count \\\u003C 1500 per cubic millimetre (\\\u003C 1,5 x 109\u002FL)\n* Platelet count \\\u003C 100 000 per cubic millimetre (\\\u003C 100 x 109\u002FL)\n* Serum creatinine \\> 1.5 UNL (upper limit normal range)\n* Albumin \\\u003C2,5 g\u002Fdl (\\\u003C25 g\u002FL)\n* Total bilirubin \\>3 x ULN\n* ASAT (SGOT) and ALAT (SGPT) \\>2.5 x institutional ULN\n* female patients in child-bearing age not using adequate contraception, pregnant or lactating women\n* mental or somatic disorders which could possibly interfere with informed consent, compliance or the planned treatments\n* previous oncologic treatment for PC within the past 5 years\n* participation in other clinical trial with an investigational product during the past 30 days\n* Any reason according to the investigator why the patient cannot comply with the protocol or is not suitable to participate","90 Years",{"count":465,"type":20},432,[103],"The goal of this multicenter randomized controlled phase III trial is to compare two durations of neoadjuvant chemotherapy (NAT) with mFOLFIRINOX or gemcitabine-nab-paclitaxel (GnP) before attempt for surgical resection in patients with borderline (BR) and locally advanced pancreatic cancer (LAPC). Patients with histologically confirmed non-metastatic BR\u002FLAPC evaluated to potentially tolerate any of the treatment regimens and pancreatic surgery will be randomized to receive either standard duration NAT with 6 cycles mFOLFIRINOX or 4 cycles GnP or prolonged duration NAT with either 12 cycles mFOLFIRINOX or 6 cycles GnP before attempt for surgical resection, provided there is no evidence of disease progression. The primary objective is to compare the overall survival at 24 months after randomization of all treated patients and among the resected patients with BR\u002FLAPC.",[27,469,342,470,471,472],"Borderline Resectable Pancreatic Carcinoma","Neoadjuvant Chemotherapy","Surgery","Pancreatectomy","2024-11-28",{"date":475,"type":33},"2024-12-03",{"date":477,"type":33},"2023-10-18",{"date":479,"type":20},"2033-12-31",{"name":481,"class":70},"Sahlgrenska University Hospital",{"id":483,"slug":484,"hasResults":11,"nctId":485,"briefTitle":486,"officialTitle":487,"acronym":488,"eligibilityCriteria":489,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":490,"targetDuration":492,"studyType":413,"phases":4,"briefSummary":493,"conditions":494,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":4},"100546763","oncosil-pancreatic-cancer-post-marketing-clinical-registry---italy-100546763","NCT06399172","OncoSil Pancreatic Cancer Post-marketing Clinical Registry - Italy","OncoSil Pancreatic Cancer Post-marketing Clinical Registry Italy","OSPRItaly","Inclusion Criteria:\n\n1. Patients who are eligible for and undergo OncoSil™ implantation at an eligible treatment facility according to the approved OncoSil™ System Instructions for Use (IFU), as part of their clinical care.\n2. Patients who have completed and signed the Patient Informed Consent Form (PICF) for the OSPRItaly Patient Registry.\n\nExclusion Criteria:\n\n1. Patients participating in an interventional clinical study (company or investigator-sponsored).\n2. Use of an investigational agent at the time of enrolment.",{"count":491,"type":20},50,"1 Year","The OSPRItaly Patient Registry has been developed to assess the performance and safety of the OncoSil™ device when used within the approved indication of unresectable, locally advanced pancreatic cancer, in combination with gemcitabine-based chemotherapy, within a real-world observational registry.",[27],"2024-05-01",{"date":497,"type":33},"2024-05-03",{"date":499,"type":20},"2024-05-30",{"date":501,"type":20},"2029-10-30",{"name":503,"class":140},"OncoSil Medical Limited",{"id":505,"slug":506,"hasResults":11,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":510,"eligibilityCriteria":511,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":512,"targetDuration":4,"studyType":21,"phases":513,"briefSummary":514,"conditions":515,"keywords":516,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":525,"locationsCount":194},"100537002","locally-advanced-pancreatic-cancer-after-systemic-therapy-ablative-mr-guided-radiotherapy-100537002","NCT06272162","Locally Advanced Pancreatic Cancer After Systemic Therapy: Ablative MR-guided Radiotherapy","Locally Advanced Pancreatic Cancer After Systemic Therapy: Ablative MR-guided Radiotherapy, a Randomized Controlled Trial","LAPSTAR","Inclusion Criteria:\n\n* Pathology proven pancreatic ductal adenocarcinoma (PDAC);\n* At least two (preferably four) months systemic therapy with (m)FOLFIRINOX and\u002For gemcitabine + nab-paclitaxel; or eligibility for chemotherapy but no initiation of chemotherapy based on patients' wish;\n* No option for surgical resection, either because anatomical irresectability based on the surgeon's judgement (assessed on imaging or during explorative laparotomy) and\u002For frailty (unfit for surgery or chemotherapy) and\u002For no surgery based on patient's wish.\n* No evidence of distant metastatic disease progression, evaluated by CT Thorax \u002F Abdomen \u002F Pelvis and\u002For PET-CT scan;\n* Performance status WHO 0-2.\n\nExclusion Criteria:\n\n* Contra-indications for MRI or CT with an intravenous contrast agent according to the protocol of the local radiology and\u002For radiotherapy departments\n\n  * Contraindications for MRgRT, as determined by the involved expert radiation oncologists of the Consortium\n  * \\\u003C18 years old\n  * Pregnancy",{"count":412,"type":20},[339],"A randomized controlled trial comparing the effect of local ablative MR-guided radiotherapy (MRgRT) after systemic therapy with current standard treatment alone, on health-related quality of life in patients with locally advanced pancreatic cancer (LAPC).",[27],[517],"MR guided radiation therapy","2024-02-14",{"date":520,"type":33},"2024-02-22",{"date":522,"type":20},"2024-02",{"date":524,"type":20},"2030-01",{"name":526,"class":70},"UMC Utrecht",{"id":528,"slug":529,"hasResults":11,"nctId":530,"briefTitle":531,"officialTitle":532,"acronym":533,"eligibilityCriteria":534,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":535,"targetDuration":4,"studyType":413,"phases":4,"briefSummary":537,"conditions":538,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":543,"startDateStruct":545,"completionDateStruct":547,"leadSponsor":549,"locationsCount":71},"100466615","survival-quality-of-life-and-resectability-in-locally-advanced-pancreatic-cancer-100466615","NCT05356039","Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer","Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer - a Multicenter Prospective Observational Study","SQUARE","Inclusion Criteria:\n\n* Confirmed or suspected invasive pancreatic primary tumor\n* Tumor classified as borderline resectable or locally advanced disease according to NCCN guidelines\n\nExclusion Criteria:\n\n* Suspected endocrine tumor\n* Suspected non-pancreatic periampullary tumor\n* Distant metastasis\n* Age \\\u003C 18 years\n* Patient unable to understand verbal or written information interfering with informed consent or treatment\n* Mental or organic disorder interfering with informed consent or treatments",{"count":536,"type":20},300,"This study aims to assess overall survival, quality of life and resection rates in locally advanced pancreatic cancer",[342,539,540,287,471,541,419,27,131],"Pancreas Neoplasm","Pancreas Disease","Chemotherapy Effect","2022-11-23",{"date":544,"type":33},"2022-11-30",{"date":546,"type":33},"2022-04-19",{"date":548,"type":20},"2028-05",{"name":550,"class":70},"Umeå University",{"id":552,"slug":553,"hasResults":11,"nctId":554,"briefTitle":555,"officialTitle":556,"acronym":557,"eligibilityCriteria":558,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":559,"targetDuration":561,"studyType":413,"phases":4,"briefSummary":562,"conditions":563,"keywords":565,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":572,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":578,"locationsCount":71},"100479523","preopanc-4-implementation-program-for-locally-advanced-pancreatic-cancer-100479523","NCT05524090","PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer","Nationwide Implementation Program for Optimal Multidisciplinary Management and Resection of Locally Advanced Pancreatic Cancer (PREOPANC-4)","PREOPANC-4","Inclusion Criteria:\n\n* Age 18 years or older\n* Pathology-confirmed (LAPC)\\*\n* CT-based non-progressive disease (RECIST criteria) after at least 4 months of systemic chemotherapy (\\[m\\]FOLFIRINOX \u002F gemcitabine-nab-paclitaxel).\n\nExclusion Criteria:\n\n* Metastatic pancreatic cancer prior to induction chemotherapy.\n\n  * According to the Dutch Pancreatic Cancer Group (DPCG) definition: \\>90 degrees arterial tumor involvement (i.e. superior mesenteric artery, celiac axis, and\u002For hepatic artery) and\u002For portovenous involvement of either \\>270 degrees or occlusion.",{"count":560,"type":20},223,"60 Months","A prospective, nationwide, implementation program of the international standard of excellence for locally advanced pancreatic cancer (LAPC) care in the Netherlands (2021\\[7\\]-2030\\[6\\]), including a multidisciplinary training program by the four leading international expert centers.\n\nThe PREOPANC-4 project aims a safe and patient-centered implementation of the international standards of excellence for LAPC (surgery) in the Netherlands.",[132,27,564,541],"Pancreatic Adenocarcinoma Non-resectable",[566,567,568,569,570],"Nationwide implementation International Best-Practice","The Netherlands","International Best-Practice","Patient Selection","Patient-centered","2022-08-29",{"date":573,"type":33},"2022-09-01",{"date":575,"type":33},"2021-07-01",{"date":577,"type":20},"2030-12-31",{"name":579,"class":70},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)"]